Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
Nuvec®’s potential in the fight for a vaccine against COVID-19
Our CEO, Nigel Theobald, has written an article for Drug Discovery Today about the emerging vaccine delivery systems for COVID-19. He talks about how functionalised silica nanoparticles, like Nuvec®, offer a potentially safe and effective [...]
Directors Talk interview: N4 Pharma is “entering a defining period”
After the release of our interim results this week, we're pleased to share another interview between N4 Pharma's CEO, Nigel Theobald, and Directors Talk. Nigel discusses the progress made with Nuvec® research projects in the [...]
Proof of concept project update: interview with Directors Talk
N4 Pharma's CEO, Nigel Theobald, has spoken to Directors Talk to give an update on our Covid-19 proof of concept project, and our ongoing work to show Nuvec®'s potential use with multiple vaccines. Watch the [...]